Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telaprevir response-guided duration study in treatment-naive genotype 1 chronic hepatitis C
NL-OMON33525Phase 3Not yet recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Sep 2008
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of telaprevir, interferon alfa and ribavirin in chronic hepatitis C virus infection (2 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Sustained viral response in randomized subjects. Planned start Sep 2008; status: not yet recruiting.
02
Drugs
telaprevirinterferon alfaribavirin
03
Conditions
chronic hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON33525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33525.